The anti suicidal drugs market is anticipated to grow at a significant CAGR of 4.1% during the forecast period. The market is growing due to the high prevalence of depression that leads to suicide attempts and the introduction of several novel drugs. According to FDA, depression is considered a disabling illness that is expected to lead to suicidal thoughts among people. So, pharmaceuticals companies are launching specific drugs for suicidal impulses and driving the growth of the market. Additionally, the off-label recommendation and prescription of anti-depressant and anti-anxiety drugs are also acting as the factor for the growth of the market. However, the insufficient reach of healthcare facilities and unaffordable medication are the major restraining factor for the global anti suicidal drugs market to grow in certain regions. 

Impact of COVID-19 Pandemic on Global Anti Suicidal Drugs Market

The COVID-19 had impacted the market positively. According to a study by the National Library of Medicine, COVID-19 was associated with distress, anxiety, fear of contagion, depression, and insomnia. Social isolation, fear of contagion, and the uncertainty of life and economics lead to the development of depression, anxiety, and other psychiatric disorder among the population. So, to reduce stress and anxiety among the population, doctors had prescribed anti suicidal drugs to patients with psychiatric and bipolar disorder which have increased the demand for the anti suicidal drugs market globally during the COVID-19 pandemic.

Segmental Outlook 

The global anti suicidal drugs market is segmented based on the drug type and distribution channel. Based on the drug type, the market is segmented into anti-depressant & anti-anxiety drug, N-Methyl-D-Aspartate receptor antagonists, antibiotic analog, anti-psychotic drug, and others. Based on the distribution channel, the market is sub-segmented into an online pharmacy and offline pharmacy. Amongst the drug type, the N-Methyl-D-Aspartate receptor antagonist is anticipated to hold a prominent share in the global anti suicidal drugs market. Amongst the distribution channel, the offline pharmacy is anticipated to hold the major share in the global anti suicidal drugs market. 

Global Anti Suicidal Drugs Market Share by Drug Type, 2021 (%)

The N-Methyl-D-Aspartate Receptor Antagonists is Anticipated to Hold the Significant Share in the anti suicidal drugs Market

The N-Methyl-D-Aspartate receptor antagonists drug is anticipated to hold a significant share in the global anti suicidal drugs market. This is due to N-Methyl-D-Aspartate receptor antagonists drug had received special attention in psychiatric disorders. It has been tested in different animal models and then approved by FDA and has more anti-depressant effects after 2 months of taking the drug. So, doctors generally prescribe N-Methyl-D-Aspartate receptor antagonist drugs to treat depression and anxiety in bipolar disorder patients and anticipated to propel the market in the forecast period.

Regional Outlooks

The global anti suicidal drugs market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, and Others), and the Rest of the World (the Middle East &Africa, and Latin America. The Asia-Pacific region is expected to witness significant growth opportunities for the market. Increasing health awareness among people likely to drive the growth of the regional market. Additionally, the rising demand for novel drug discovery technologies due to the increasing population in this region especially in India, China and Japan are impacting the market along with growing number of research organization (CROs) and favorable government policy is driving the growth of the market in the region.

Global Anti-Suicidal Drug Market Growth, by Region 2022-2028

The North America Region is estimated to Hold the Significant Share in the Anti Suicidal Drugs Market

North America is anticipated to hold the significant share in the anti suicidal drugs market. North America provides better medical care and considered as the early adopters of new treatments which is supporting the market growth. Additionally, the well-equipped healthcare infrastructure in this region and the increasing prevalence of suicides in this region is boosting the market growth. Additionally, government initiatives and NGO’s working together to aware people about suicides are supporting the North American anti suicidal drugs market to hold the major market share.

Market Players Outlook

The major companies serving the anti suicidal drugs market include Allergan, AstraZeneca, Eli Lilly and Co., GlaxoSmithKline, Pfizer Inc., and many more. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, collaborations, funding, and new product launches for the advancement of the product, to stay competitive in the market. For instance, in March 2019, VistaGen Therapeutics, a biopharmaceutical company is developing new general medicine to treat depression, social anxiety disorder, and central nervous system disease.

The Report Covers

• Market value data analysis of 2022 and forecast to 2028.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global anti suicidal drugs market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.